Karyopharm Therapeutics Inc (NASDAQ: KPTI) started the day on Wednesday, with a price decrease of -4.76% at $0.60, before settling in for the price of $0.63 at the close. Taking a more long-term approach, KPTI posted a 52-week range of $0.58-$1.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 56.57%. Meanwhile, its Annual Earning per share during the time was 16.79%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 6.76%. This publicly-traded company’s shares outstanding now amounts to $125.30 million, simultaneously with a float of $114.13 million. The organization now has a market capitalization sitting at $75.71 million. At the time of writing, stock’s 50-day Moving Average stood at $0.6767, while the 200-day Moving Average is $0.8369.
Karyopharm Therapeutics Inc (KPTI) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Karyopharm Therapeutics Inc’s current insider ownership accounts for 9.56%, in contrast to 47.39% institutional ownership. According to the most recent insider trade that took place on Feb 18 ’25, this organization’s EVP, Chief Development Officer sold 5,914 shares at the rate of 0.63, making the entire transaction reach 3,726 in total value, affecting insider ownership by 320,714. Preceding that transaction, on Feb 04 ’25, Company’s President and CEO sold 4,099 for 0.65, making the whole transaction’s value amount to 2,664. This particular insider is now the holder of 1,120,158 in total.
Karyopharm Therapeutics Inc (KPTI) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
Karyopharm Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 6.76% and is forecasted to reach -0.55 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 30.52% through the next 5 years, which can be compared against the 16.79% growth it accomplished over the previous five years trading on the market.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) Trading Performance Indicators
Let’s observe the current performance indicators for Karyopharm Therapeutics Inc (KPTI). It’s Quick Ratio in the last reported quarter now stands at 2.93. The Stock has managed to achieve an average true range (ATR) of 0.05. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.51.
In the same vein, KPTI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.14, a figure that is expected to reach -0.27 in the next quarter, and analysts are predicting that it will be -0.55 at the market close of one year from today.
Technical Analysis of Karyopharm Therapeutics Inc (KPTI)
If we take a close look at the recent performances of Karyopharm Therapeutics Inc (NASDAQ: KPTI), its last 5-days Average volume was 1.14 million that shows progress from its year to date volume of 0.85 million. During the previous 9 days, stock’s Stochastic %D was recorded 42.51% While, its Average True Range was 0.0515.
Raw Stochastic average of Karyopharm Therapeutics Inc (KPTI) in the period of the previous 100 days is set at 11.67%, which indicates a major fall in contrast to 41.67% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 58.60% that was lower than 81.66% volatility it exhibited in the past 100-days period.
